Mazdutide Demonstrates Efficacy in Managing Type 2 Diabetes in Chinese Patients

1 min read
Source: Nature
TL;DR Summary

A phase 3 trial in Chinese adults with type 2 diabetes showed that mazdutide, a dual GCGR/GLP-1R agonist, significantly improved glycemic control and promoted weight loss compared to placebo, with a favorable safety profile.

Share this article

Reading Insights

Total Reads

0

Unique Readers

2

Time Saved

4 min

vs 4 min read

Condensed

95%

75334 words

Want the full story? Read the original article

Read on Nature